Key result
R-CHOP stabilizes disease in a patient with intravascular large B-cell lymphoma presenting as ILD.
Why the study?
Intravascular large B-cell lymphoma usually spares the lymph nodes and rarely presents as diffuse interstitial lung disease.
Case Report (n=1)
Yes
This case demonstrates that intravascular large B-cell lymphoma can present atypically with diffuse interstitial lung disease and generalized lymphadenopathy, expanding its recognized phenotypic spectrum.
No takes yet. Share an insight, caveat, or question.
May support R-CHOP in CD30-positive IVLBCL with atypical pulmonary presentation; extends phenotypic spectrum and is hypothesis-generating.
Wang et al. (2026) conducted a case report in 62-year-old male patient with CD30-positive intravascular large B-cell lymphoma presenting as diffuse interstitial lung disease and generalized lymphadenopathy (n=1). R-CHOP chemotherapy (rituximab, cyclophosphamide, pirarubicin, vincristine, prednisone) was evaluated on Disease remission and stability post-treatment. R-CHOP chemotherapy led to disease stability in a 62-year-old male with CD30-positive intravascular large B-cell lymphoma presenting as diffuse interstitial lung disease and generalized lymphadenopathy after 8 cycles over 6 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: